Complete financial analysis of Lantern Pharma Inc. (LTRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lantern Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Fluidra, S.A. (FLUIF) Income Statement Analysis – Financial Results
- Atlas Financial Holdings, Inc. (AFHIQ) Income Statement Analysis – Financial Results
- Baillie Gifford European Growth Trust plc (BGEU.L) Income Statement Analysis – Financial Results
- OVAL Corporation (7727.T) Income Statement Analysis – Financial Results
- South West Pinnacle Exploration Limited (SOUTHWEST.BO) Income Statement Analysis – Financial Results
Lantern Pharma Inc. (LTRN)
About Lantern Pharma Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 174.84K | 154.68K | 97.42K | 3.39K | 1.63K | -2.54K |
| Gross Profit | -174.84K | -154.68K | -97.42K | -3.39K | -1.63K | 2.54K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.89M | 8.60M | 7.57M | 2.24M | 953.19K | 572.10K |
| General & Administrative | 5.98M | 5.83M | 5.02M | 3.66M | 1.48M | 1.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.98M | 5.83M | 5.02M | 3.66M | 1.48M | 1.15M |
| Other Expenses | 0.00 | -31.55K | 160.55K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.88M | 14.43M | 12.59M | 5.91M | 2.43M | 1.73M |
| Cost & Expenses | 17.88M | 14.43M | 12.59M | 5.91M | 2.43M | 1.73M |
| Interest Income | 765.39K | 204.36K | 67.93K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 204.36K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 174.84K | 154.68K | 97.42K | 3.39K | 1.63K | -2.54K |
| EBITDA | -15.79M | -14.42M | -12.27M | -5.90M | -2.43M | -1.73M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.88M | -14.43M | -12.59M | -5.91M | -2.43M | -1.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.92M | 172.81K | 228.48K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -15.96M | -14.26M | -12.36M | -5.91M | -2.43M | -1.73M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -172.81K | -67.93K | -202.91K | -5.00 | 2.54K |
| Net Income | -15.96M | -14.09M | -12.30M | -5.91M | -2.43M | -1.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.47 | -1.30 | -1.13 | -0.95 | -0.39 | -0.28 |
| EPS Diluted | -1.47 | -1.30 | -1.13 | -0.95 | -0.39 | -0.28 |
| Weighted Avg Shares Out | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M | 6.22M |
| Weighted Avg Shares Out (Dil) | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M | 6.22M |
3 Penny Stocks to Buy as the AI Sector Transforms Every Industry in 2023
Lantern Pharma Inc. (LTRN) Q1 2023 Earnings Call Transcript
Lantern Pharma Inc. (LTRN) Q4 2022 Earnings Call Transcript
LTRN Stock: 7.74% Increase After Hours Explanation
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
Lantern Pharma said it had no exposure to SVB or Signature Bank, after stock plunged last week
7 AI Penny Stocks That Could Skyrocket in 2023
ProPhase Labs Discloses 8.4% Position in LTRN / Lantern Pharma After Q3 Results
Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET
Source: https://incomestatements.info
Category: Stock Reports